{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for ethanolamine root_references_citation in Reference Text / Citation (approximate match)
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 333A
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 348
(2017)
Source URL:
First approved in 2017
Source:
21 CFR 348
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
M020
(2025)
Source URL:
First approved in 2017
Source:
21 CFR 348
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
M016
(2023)
Source URL:
First approved in 2016
Source:
21 CFR 347
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
Krx Aesthetics All Day Glow Sunblocker by KRX RESOURCES SDN. BHD.
(2024)
Source URL:
First approved in 2011
Source:
21 CFR 352
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
ANDA065078
(2005)
Source URL:
First approved in 2005
Source:
ANDA065078
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 333C
(2003)
Source URL:
First approved in 2003
Source:
21 CFR 333C
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Class:
POLYMER
Status:
US Approved Rx
(2023)
Source:
ANDA214950
(2023)
Source URL:
First marketed in 1921
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Since its discovery as component of the tea leaf by Albert Kossel in 1888, the history of theophylline (CAS 58-55-9) has been a long and successful one. At the turn of the century, theophylline became less expensive due to chemical synthesis and was primarily used as diuretic in subsequent years. It was Samuel Hirsch who discovered the bronchospasmolytic effect of theophylline in 1992, however, despite this pioneering discovery theophylline continued to be used primarily as diuretic and cardiac remedy. The molecular mechanism of bronchodilatation is inhibition of phosphodiesterase(PDE)3 and PDE4, but the anti-inflammatory effect may be due to histone deacetylase (HDAC) activation, resulting in switching off of activated inflammatory genes.
Theophylline is indicated for the treatment of acute exacerbations of the symptoms and reversible airflow obstruction associated with asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis.
